Aimmune Therapeutics Inc (OQ:AIMT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 8000 Marina Blvd Ste 300
BRISBANE CA 94005-1884
Tel: 1-650-3765582
IR: See website
Key People
Mark D. McDade
Independent Chairman of the Board
Jayson Dallas
President, Chief Executive Officer, Director
Eric H. Bjerkholt
Chief Financial Officer
Mary M. Rozenman
Senior Vice President - Corporate and Strategy Development
Douglas T. Sheehy
General Counsel, Secretary
Daniel C. Adelman
Chief Medical Officer
Andrew Oxtoby
Chief Commercial Officer
Business Overview
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company's lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
Financial Overview
For the fiscal year ended 31 December 2019, Aimmune Therapeutics Inc revenues was not reported. Net loss increased 18% to $248.5M. Higher net loss reflects Employee-related costs increase from $27.9M to $68.3M (expense), General and Administrative - other increase of 64% to $59.4M (expense), Employee-related costs increase of 95% to $44.7M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.67 to -$3.97.
Employees: 215 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $843.87M as of Dec 31, 2019
Annual revenue (TTM): $0.00M as of Dec 31, 2019
EBITDA (TTM): -$245.72M as of Dec 31, 2019
Net annual income (TTM): -$248.50M as of Dec 31, 2019
Free cash flow (TTM): -$203.46M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 65,041,825 as of Feb 14, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization